1-13 of 13
Tadaaki Yamada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers

Available to Purchase
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, Sachiko Arai, Yasuhiro Goto, Yoshihiko Sakata, Kazumi Nishino, Michiko Tsuchiya, Akihiro Tamiya, Go Saito, Satoshi Muto, Takayuki Takeda, Koji Date, Yasuhito Fujisaka, Satoshi Watanabe, Daichi Fujimoto, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Seiji Yano, Shinsaku Tokuda, Koichi Takayama
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (6): 1127–1141.
https://doi.org/10.1158/1078-0432.CCR-24-1762
Published: 17 March 2025
View articletitled, YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Open the PDF for YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers in another window
Includes: Supplementary data
Journal Articles

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer

Available to Purchase
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, Takeshi Kitazaki, Akihiro Nishiyama, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Kohei Tanaka, Ryohei Kozaki, Seiji Yano, Koichi Takayama
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2244–2256.
https://doi.org/10.1158/1078-0432.CCR-19-2321
Published: 01 May 2020
View articletitled, ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
Open the PDF for ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model

Free
Akihiro Nishiyama, Tadaaki Yamada, Kenji Kita, Rong Wang, Sachiko Arai, Koji Fukuda, Azusa Tanimoto, Shinji Takeuchi, Shoichiro Tange, Atsushi Tajima, Noritaka Furuya, Takayoshi Kinoshita, Seiji Yano
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2357–2369.
https://doi.org/10.1158/1078-0432.CCR-17-1623
Published: 14 May 2018
View articletitled, Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Open the PDF for Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model in another window
Includes: Supplementary data
Journal Articles

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer

Free
Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S. Tiong Ong, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3139–3149.
https://doi.org/10.1158/1078-0432.CCR-16-2271
Published: 14 June 2017
View articletitled, Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Open the PDF for Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells

Free
Seiji Yano, Shinji Takeuchi, Takayuki Nakagawa, Tadaaki Yamada
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR7.
https://doi.org/10.1158/1078-0432.MECHRES-PR7
Published: 04 March 2013
View articletitled, Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells
Open the PDF for Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells in another window
Journal Articles

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Free
Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Kenji Kita, Takayuki Nakagawa, Shigeki Nanjo, Takahiro Nakamura, Kunio Matsumoto, Manabu Soda, Hiroyuki Mano, Toshimitsu Uenaka, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (13): 3592–3602.
https://doi.org/10.1158/1078-0432.CCR-11-2972
Published: 01 July 2012
View articletitled, Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
Open the PDF for Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

Free
Wei Wang, Qi Li, Shinji Takeuchi, Tadaaki Yamada, Hitomi Koizumi, Takahiro Nakamura, Kunio Matsumoto, Naofumi Mukaida, Yasuhiko Nishioka, Saburo Sone, Takayuki Nakagawa, Toshimitsu Uenaka, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1663–1671.
https://doi.org/10.1158/1078-0432.CCR-11-1171
Published: 14 March 2012
View articletitled, Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Open the PDF for Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells

Free
Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Kenji Kita, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B21.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B21
Published: 01 February 2012
View articletitled, Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells
Open the PDF for Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells in another window
Journal Articles

The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer

Free
Kazuo Yasumoto, Tadaaki Yamada, Atsuhiro Kawashima, Wei Wang, Qi Li, Ivan Shterev Donev, Shinji Tacheuchi, Hisatsugu Mouri, Kaname Yamashita, Koushiro Ohtsubo, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3619–3630.
https://doi.org/10.1158/1078-0432.CCR-10-2475
Published: 01 June 2011
View articletitled, The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer
Open the PDF for The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Free
Ivan S. Donev, Wei Wang, Tadaaki Yamada, Qi Li, Shinji Takeuchi, Kunio Matsumoto, Takao Yamori, Yasuhiko Nishioka, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2260–2269.
https://doi.org/10.1158/1078-0432.CCR-10-1993
Published: 14 April 2011
View articletitled, Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Open the PDF for Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

Free
Tadaaki Yamada, Kunio Matsumoto, Wei Wang, Qi Li, Yasuhiko Nishioka, Yoshitaka Sekido, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 174–183.
https://doi.org/10.1158/1078-0432.CCR-09-1204
Published: 04 January 2010
View articletitled, Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Open the PDF for Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles

Free
Kenji Ikuta, Seiji Yano, Van The Trung, Masaki Hanibuchi, Hisatsugu Goto, Qi Li, Wei Wang, Tadaaki Yamada, Hirokazu Ogino, Soji Kakiuchi, Hisanori Uehara, Yoshitaka Sekido, Toshimitsu Uenaka, Yasuhiko Nishioka, Saburo Sone
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7229–7237.
https://doi.org/10.1158/1078-0432.CCR-09-1980
Published: 30 November 2009
View articletitled, E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
Open the PDF for E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles in another window
Journal Articles

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Free
Wei Wang, Qi Li, Tadaaki Yamada, Kunio Matsumoto, Isao Matsumoto, Makoto Oda, Go Watanabe, Yoshiyuki Kayano, Yasuhiko Nishioka, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6630–6638.
https://doi.org/10.1158/1078-0432.CCR-09-1001
Published: 02 November 2009
View articletitled, Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Open the PDF for Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in another window
Includes: Supplementary data